Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Metastasis ; 10(1): 39-47, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1733646

ABSTRACT

We report on the inhibition of wound implantation by TA3Ha mammary carcinoma cells by Arg-Gly-Asp containing proteins and peptides using a hepatic wedge resection model. Intravenously injected TA3Ha cells rarely form tumor in the liver of syngeneic mice, but after hepatic wedge resection, 45% (107/240) of the mice develop tumors in the hepatic wound. Hepatic wound implantation is significantly (P = 0.01) inhibited by pretreating the cells with whole mouse plasma, but not with fibrinogen-depleted plasma or serum. Tumor inhibition is also achieved by pretreatment of cells with fibrinogen (P = 0.05-0.0004), fibronectin (P = 0.007) and laminin, but not by albumin. The active domain appears to be the RGDS sequence since the deca- and tetrapeptides containing RGDS inhibit wound implantation (P less than 0.05). However, the tetrapeptide Arg-Gly-Glu-Ser has no such activity. None of these agents affects ascites tumor formation by the intraperitoneally injected cells, suggesting that anchorage independent growth of cells is not affected. We propose that proteins and peptides containing RGD occupy the binding sites and prevent the cells from interacting with cell adhesion proteins in healing wounds. Proteins and/or peptides containing RGD may be useful for preventing local recurrence in postsurgical cancer patients.


Subject(s)
Liver Neoplasms/prevention & control , Liver Neoplasms/secondary , Liver/injuries , Lung Injury , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Mammary Neoplasms, Animal , Oligopeptides/pharmacology , Animals , Female , Mice , Neoplasm Transplantation , Proteins/chemistry
2.
JAMA ; 244(3): 243-6, 1980 Jul 18.
Article in English | MEDLINE | ID: mdl-6991733

ABSTRACT

Stage II or III breast carcinoma patients were assigned to one of three adjuvant chemotherapy groups after mastectomy. The efficacy of melphalan, vs cyclophosphamide, fluorouracil, and prednisone (CFP), vs CFP plus BCG vaccine was compared in 173 patients treated for five days every six weeks for the first postoperative year. Tumor size, unfavorable local signs, extent of axillary nodal involvement, menopausal status, and participating hospital were considered in assigning patients to treatment groups. The median follow-up time was 26 months; 24.2% of the patients were studied for more than three years. Recurrent disease occurred in 31.6% of the patients in the melphalan group and in 13.4% and 13.2% in the other two groups. Six patients died of metastatic tumor; three others died of other causes. A favorable significant difference exists for polychemotherapy in prolonging disease-free interval in our series.


Subject(s)
BCG Vaccine/administration & dosage , Breast Neoplasms/drug therapy , Antineoplastic Agents/administration & dosage , Breast Neoplasms/pathology , Clinical Trials as Topic , Drug Therapy, Combination , Female , Humans , Mastectomy , Melphalan/therapeutic use , Neoplasm Staging , Postoperative Care , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...